SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology areas. It operates manufacturing and distribution facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The company emphasizes ongoing research to create therapies that address unmet medical needs and to improve patient outcomes. Its portfolio spans treatments for diabetes and metabolic conditions, cancer, autoimmune diseases, and other serious conditions.

Novo Nordisk is a global pharmaceutical company headquartered in Denmark that discovers, develops, manufactures, and markets medicines primarily for diabetes care and related chronic diseases. Its portfolio includes insulin therapies and other diabetes treatments, with a growing focus on obesity management, growth disorders, haemophilia, and cardiovascular conditions. The company emphasizes research and development to advance innovative therapies, including metabolic and cardiometabolic medicines, and aims to expand access to essential medicines worldwide. Novo Nordisk places a strong emphasis on patient safety, sustainability, governance, and transparent reporting, reflecting responsible business practices and ESG commitments. Operating globally, it pursues collaborations and partnerships to address global health needs and strives to improve health outcomes through scientific excellence and responsible stewardship of resources.

Qiming Venture Partners is a global venture capital firm founded in 2006 with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds and more than $9.5 billion in committed capital, investing across healthcare, information technology, new consumer patterns, mobile internet, AI, robotics, and related sectors. The firm backs early to growth-stage companies, including numerous healthcare, tech and consumer businesses, and has built a broad portfolio exceeding several hundred companies with a substantial track record of exits, including IPOs and M&A. It operates a U.S. presence to back cross-border opportunities and emphasizes a hands-on approach, leveraging industry resources and an extensive network to support portfolio companies through strategic decisions, governance, and scaling. The portfolio spans marquee names and innovative startups, reflecting a focus on accelerating China's innovation and delivering long-term value for entrepreneurs and stakeholders.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focused on life sciences. It invests in startups from seed to later stages in biopharmaceuticals, biotech, medical devices, industrial biotechnology, and related healthcare technologies. The firm often takes lead or cornerstone roles in rounds, sits on boards, and provides active support from formation onward to help entrepreneurs develop transformative innovations. It also considers corporate spin-offs and occasional turnaround opportunities, with the aim of delivering meaningful health advances alongside attractive returns for investors.

Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines to address unmet medical needs. It maintains a broad portfolio across prescription medicines, vaccines, and treatments spanning internal medicine, inflammation and immunology, oncology, and other therapeutic areas, and it operates a sizable pipeline of investigational products with potential to address major diseases. The company conducts extensive global sales, with international markets contributing a substantial share of revenue, and it emphasizes scientific innovation, transparency, patient access, and ethical business practices. Its well-known products include Prevnar 13 and Eliquis, among others, and it continues to invest in research and development to advance new therapies. Based in the United States, Pfizer has a long history dating back to the 19th century and maintains a global footprint through manufacturing, partnerships, and philanthropic initiatives aimed at improving health outcomes worldwide.

Redmile Group is a San Francisco based investment firm specializing in healthcare, life sciences and related technology sectors. It pursues venture, growth, and crossover investments and provides strategic capital and operating experience to portfolio companies, supporting growth initiatives, acquisitions, and strategic partnerships. With offices in San Francisco and New York, the firm takes a hands-on approach, applying deep industry knowledge and networks to help portfolio companies scale and create long-term value for investors.

Venrock is a Palo Alto-based venture capital firm, founded in 1969 as the venture capital arm of the Rockefeller family. It focuses on seed and early-stage investments in technology and healthcare, supporting founders with strategic guidance and long-term growth. The firm has backed a broad portfolio of notable companies across software, semiconductors, healthcare, and consumer technology, including Apple, Intel, Illumina, Nest, Gilead Sciences, DoubleClick, Athenahealth, Endeca, SlideShare, and Tudou. With offices in Silicon Valley and New York, Venrock emphasizes partnership with entrepreneurs to build enduring companies through hands-on mentorship, sector expertise, and a long-term orientation. Its activity spans multiple technology and life sciences domains, including cybersecurity, AI, and digital health, reflecting a consistent track record of helping portfolio companies scale and achieve exits.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Deerfield Management is a New York City–based healthcare investment and information platform that advances health outcomes through flexible funding, data-driven insights, and philanthropic support. The firm invests in and builds healthcare companies across biotechnology, pharmaceuticals, diagnostics, medical devices, healthcare services, and digital health, leveraging a dedicated research and development engine, Deerfield Discovery and Development, and in-house facilities that support scientific collaboration and discovery. Its Intelligence offering uses AI, data and market research to drive technology and strategy across its portfolio and the broader healthcare ecosystem. Deerfield operates the Cure hub housing portfolio companies and modern labs, and has partnered with organizations such as Blue Cross Blue Shield of North Carolina to develop services like Alo that assist independent physicians in managing the business of medicine. The Deerfield Foundation funds education, healthcare access and health outcomes initiatives, reflecting a broader philanthropic approach to accelerating medical innovation through partnerships and strategic collaborations.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Illumina is a biotechnology company that develops and markets sequencing instruments, consumables, and related services to support genetic analysis across life sciences and clinical applications. Its high-throughput sequencing platforms enable whole genome sequencing in humans and other organisms, while lower-throughput tools support targeted testing for viral, cancer, and translational research applications. The company also offers array-based solutions for DNA, RNA, and protein analysis used in disease research, drug development, and the development of molecular tests for clinical use. Illumina emphasizes scalable, flexible solutions and strong customer support, focusing on rapid delivery of genomics-enabled insights and collaborative interactions with researchers, clinicians, and industry partners. By providing an integrated ecosystem that includes instruments, reagents, and data-analysis tools, Illumina aims to advance personalized medicine and accelerate discoveries in genomics, life sciences, and healthcare.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a history spanning more than five decades and offices in London and San Francisco. It invests across healthcare and technology, including life sciences, therapeutics, medtech, healthtech and services, enterprise software, fintech, frontier tech, and crypto, with a global reach across the Americas, Europe, and Asia. The firm emphasizes backing ambitious teams at any stage and leverages a team of scientists, engineers, physicians, operators, and investors to support rapid, scalable growth. Known for thoughtful collaboration and a focus on impact, F-Prime leverages its experience to help portfolio companies navigate scientific, technical, and market challenges, aiming to drive breakthroughs in healthcare and technology and to advance bold, transformative ideas.

Flagship Pioneering is a Cambridge, Massachusetts-based venture builder that conceives, creates, resources, and scales first-in-category companies in health, biotechnology, and sustainability. It turns early scientific breakthroughs into durable platforms and enterprises by combining scientific discovery with entrepreneurial leadership and capital management, pursuing transformative outcomes through an evolutionary approach. With more than 25 years of experience, Flagship builds ecosystems that connect science, startups, and collaboration across partners. Notable portfolio companies include Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, Lila Sciences, and Serif Biomedicines, reflecting a focus on pioneering medicines, intelligence, and preemptive health. The firm collaborates with major partners such as Genentech, Pfizer, GSK, Novo Nordisk, and Montai Therapeutics and engages in technology partnerships like AWS to accelerate discovery. Flagship emphasizes global health impact and disruptive science, fostering programs and opportunities through initiatives such as the Flagship Fellowship.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including oncology and drug discovery. It supports startups from early discovery through commercialization, taking a long-term view to build companies around robust scientific platforms and multiple product opportunities rather than short-term exits. The firm emphasizes deep scientific expertise, strong teams, collaboration, and mentorship, exemplified by the Swanson Fellowship. It manages more than $4 billion in assets and has backed about 55 biotech companies, generating substantial returns and multiple exits. The organization operates a portfolio of funds to support its activities from discovery to market and maintains an edge-to-edge, long-term investment approach.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the firm concentrates on life sciences, digital health and health tech, and related technologies, including diagnostics, therapeutics, artificial intelligence and machine learning. It seeks to back companies translating scientific advances into practical solutions with significant societal impact, combining rigorous scientific assessment with strategic partnerships to support research, development and commercialization.

HBM Healthcare Investments is a Swiss investment company that concentrates on the global healthcare sector, seeking to capitalize on innovation across private and public healthcare companies. Founded in 2001 and based in Switzerland, it maintains a diversified portfolio spanning human medicine, biotechnology, medical technology and diagnostics, with investments across private companies, public equities, and funds. The firm emphasizes high-value creation potential through its portfolio and positions itself to benefit from demographic trends, medical advancements and rising demand for new therapies.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. It partners with entrepreneurs to fund and accelerate the development of novel therapeutics, translating scientific insight into strategic value for portfolio companies and aiming to bring life-saving medicines to patients. The firm seeks long-term collaborations across biology and chemistry to capture breakthroughs at the molecular level and expand the drug discovery toolkit.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Boxer Capital is the corporate venture capital arm of Tavistock Group that concentrates its investments in biotechnology and life sciences. Based in San Diego, California, the firm pursues opportunities in both private and public biotechnology companies across the entire drug development lifecycle, from early discovery assets to late-stage clinical and commercial programs. It combines scientific expertise with investment experience to evaluate targets across therapeutic areas, emphasizes precision medicine, and seeks to support transformative medical advances through disciplined, research-driven analysis and active partnerships with portfolio companies.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Nextech Invest is a Zurich-based investment firm that targets early-stage healthcare and life sciences companies globally. It focuses on precision medicine and oncology, supporting ventures developing cancer therapies, diagnostics, and related technologies. The firm emphasizes scientific validation and value creation, provides targeted funding and strategic guidance, and seeks board positions in its portfolio companies. Active across Europe and beyond, it pursues interdisciplinary projects that blend biology, medicine and technology to accelerate development from discovery to market.

Kurma Partners is a Paris-based investment firm specializing in financing innovation in healthcare and biotechnology across Europe, from early development to growth-stage capital. Founded in 2009, it operates as a private equity and venture capital firm dedicated to funding therapeutic and medical innovations, and it maintains close collaboration with European academic researchers, hospitals, and institutes to translate scientific advances into medicines and medical devices. The firm supports portfolio companies through capital and strategic guidance, investing across healthcare, life sciences, digital health, and related technologies, and it maintains a network of partnerships to advance translational science, with a focus on sustainable development and ESG practices.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, biotechnology, drug delivery, medical technology, and research instruments, with additional interest in digital health and health technology. The firm maintains a Boston office and targets opportunities across the United States and North America, partnering with academics and entrepreneurs to build next-generation life science companies. It also operates an internal initiative called 4:59 to identify, incubate, and fund breakthrough science.

Seventure Partners is a Paris-based venture capital firm that acts as an active partner to innovative companies at the intersection of digital technologies and life sciences. Founded in 1997, it helps entrepreneurs translate scientific and digital breakthroughs into global businesses. The firm focuses on two main verticals: Life Sciences (biotech, healthcare, nutrition, animal health, and industrial biotech) and Digital Technologies (fintech, retailtech, cybersecurity, hardware, telecom, sports and well-being). It also backs blue economy and sustainability initiatives, including aquaculture, biopolymers and biopackaging, climate and carbon solutions, recycling, and bioenergies. With a team of experienced investors, Seventure provides strategic guidance, networks, and resources to accelerate growth for ambitious teams across Europe, North America, and beyond. The firm is based in Paris and maintains relationships with institutional partners to support its portfolio.

IP Group is a global investment company that backs science- and technology-based ventures by commercialising intellectual property generated at research-intensive institutions. It manages the entire process from identifying suitable IP to developing companies or forming commercial partnerships, leveraging deep industry and financial insight to accelerate value creation for portfolio companies, partners, and investors. The firm concentrates on healthtech, deeptech, and cleantech sectors, providing capital, strategic guidance, and operational support to help translate scientific innovations into scalable businesses. IP Group collaborates with universities, superannuation funds, and corporations to build world-class companies and deploy capital across early-stage and growth opportunities. Notable initiatives include the Climate Catalyst Fund, launched with CEFC to scale decarbonisation technologies, reflecting a track record of pursuing sustainable impact alongside financial return.

Third Rock Ventures is a Boston, Massachusetts-based venture capital firm that concentrates on early-stage life sciences investments in the United States, funding companies across pharmaceuticals, biotechnology, medical devices, diagnostics, therapeutics, oncology, and related health technologies, including information technology aspects of life sciences. The firm backs high-potential startups and commonly leads rounds, taking an active role in portfolio companies and pursuing strategic collaborations to advance development from discovery to market with a focus on patient-centered, transformative therapies and technologies.

DCVC is a deep-tech venture capital firm based in Palo Alto, California, with activities in San Francisco, that funds companies applying advanced science and engineering to major global challenges. The firm backs early- and growth-stage startups across artificial intelligence, exascale computing, climate tech, engineering, materials science, robotics, space, water, biology, defense, security, and other deep-tech sectors, and maintains specialized units such as DCVC Bio focused on life sciences. DCVC emphasizes scientifically rigorous teams and data-driven approaches, collaborating with researchers and entrepreneurs to accelerate development through AI, automation, and data-centric methods. It operates as a registered investment adviser and supports ambitious founders developing transformative technologies across software, big data, healthcare, and energy.